Evidence map›Paper›PMID 40678394›Full record

ReviewIJID regions2025

Ending tuberculosis in Gulf Cooperation Council countries: an overview of the WHO End TB Strategy 2025 milestones.

Salah Al Awaidy, Faryal Khamis, Sami Al Mujeini, Jameela Al Salman, Jaffar A Al-Tawfiq

Abstract readReview
In one paragraph

Review in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Salah Al AwaidyFreelance Public Health Consultant, Muscat, Seeb, Oman.
Faryal KhamisAdult Infectious Diseases, Department of Medicine, Royal Hospital, Ministry of Health, Muscat, Oman.
Sami Al MujeiniDepartment of Communicable Diseases and Control, General Directorate of Health Services, Ministry of Health, South Al Batinah Governorate, Oman.
Jameela Al SalmanMedical Department, King Hamed American Mission Hospital, A'Ali, Manama, Bahrain.
Jaffar A Al-TawfiqInfectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Tuberculosis (TB) continues to pose a major global public health challenge. Although the Gulf Cooperation Council (GCC) countries have lower incidence rates of TB (<10 cases per million population), they are still striving to maintain and surpass benchmarks. We describe TB status to the 2025 milestones of the World Health Organization (WHO) End TB Strategy. Methods: A retrospective study conducted using WHO data published from 2015 and between 2020 and 2023 highlights trends in TB incidence, mortality, treatment success, and drug resistance across GCC countries. Results: Kuwait had the most significant drop in TB infections since 2015, with a reduction of 57%, followed by Qatar at 40% and Saudi Arabia at 31%. Oman, however, recorded a 23% increase. In terms of TB-related deaths, Saudi Arabia achieved a 32% decrease, whereas Qatar, Kuwait, and the United Arab Emirates experienced increases of 14%, 39%, and 22% respectively. Treatment success rates were highest in Qatar (100%), Oman (90%), and Saudi Arabia (87%), whereas Kuwait (44%) and Bahrain (77%) had the lowest rates. Oman reported the highest reduction in multidrug-resistant TB cases at (60%), followed by Saudi Arabia (50%), Kuwait (31%), and Bahrain (50%). Qatar had the highest increase (122%) and United Arab Emirates had no change, reflecting varying degrees of success in controlling drug-resistant TB. HIV-TB co-infection rates was highest in United Arab Emirates (5.4%) and Bahrain (5.1%), followed by Saudi Arabia (2.3%), Oman (1.4%), Qatar (0.6%), and Kuwait (0.5%). Notably, the GCC countries reported zero TB households, with no catastrophic overall expenses since 2020. Conclusions: Although the GCC countries have made significant strides in TB control, their efforts toward the targets have been inconsistent, with notable differences in TB-related deaths, infection rates, treatment success, and multidrug-resistant TB rates. Strengthening regional collaboration, implementing targeted interventions, and integrating services are essential to meet the WHO's 2025 and 2035 goals.

Indexed as

End of TBGCC countriesTBTB eliminationWHO End TB Strategy

Identifiers

PMID40678394
PMCPMC12269608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.